Unlock the potential of our biomarker technology to uncover key insights into tissue health. Unlike traditional protein measurements that only give you an overall protein count, our biomarker technology lets you separate the building and breaking processes. This is crucial because many diseases disrupt the balance between tissue formation and breakdown, leading to issues like fibrosis or tissue loss.
In this section, you can find out how our unique markers can help your cancer study. We are leaders in measuring tumor fibrosis, a highly relevant component of the tumor microenvironment, and we also offer a selection of non-invasive immune activity biomarkers.
Nordic Bioscience is founded on a strong knowledge and curiosity in the field of bones, which have evolved into the field of joints. We therefore have a proven track record of working with biomarkers in rheumatoid arthritis, osteoarthritis and other arthritic diseases.
Nordic Bioscience's biomarkers can be of great value in hepatic diseases and liver conditions with fibrotic involvement such as NASH, Viral Liver Disease, Immune-Mediated Liver Disease (AIH, PBC and PSC), Alcoholic Liver Disease and similar conditions, and even biomarkers for liver cancer.
Nordic Bioscience has experience in measuring a variety of respiratory diseases with mode-of-action biomarkers for COPD, IPF and asthma. We also support companies in their biomarker strategy and in getting the most value. We also support companies in their biomarker strategy and in achieving the greatest benefit. We have an experienced team of scientists who are happy to assist you - please make an appointment.
We have a wide range of gastrointestinal biomarkers, especially biomarkers for ulcerative colitis and biomarkers for Crohn's disease. Our scientific team will assist you in selecting biomarkers based on your research question. On this page, you can also read the rationale behind some of our most popular biomarkers for IBD.
Read more about how you can utilize the Nordic Bioscience biomarkers in cardiovascular studies. In this section we will go into detail with our biomarkers for Myocardial Infarction, Atherosclerosis and Heart Failure (including biomarkers for HFpEF).
Our kidney team has great experience validating and measuring fibrosis markers in a wide range of renal diseases. Take a further look below to understand how we can predict response to treatment, understand disease severity and identify progressors - or catch up with a Nordic scientist. We would be pleased to provide input on your biomarker strategies.
We are doing very interesting research on applicable biomarkers for neuroscience indications. Our most advanced research is on biomarkers for Alzheimer's disease, where identifying active neurodegeneration is critical.
Skin diseases such as Systemic Sclerosis or Psoriasis are diseases with high tissue turnover. We have several markers that may be useful for biomarker strategies for these diseases. Do not hesitate to get in touch with us to reach one of the Nordic Bioscience biomarker scientists who specialize in these areas.
Metabolic dysregulation is a central part of many pathologies that may lead to multiple organ failure. Fibrosis-specific biomarkers can advance our understanding of metabolic diseases and lead to the development of more targeted treatments.
Please don't hesitate to contact us if you have any questions or other inquiries.